{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:14:20Z","timestamp":1777673660377,"version":"3.51.4"},"reference-count":45,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Innovation Fund of the Federal Joint Committee","award":["01VSF17016"],"award-info":[{"award-number":["01VSF17016"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Health\ufffdServ\ufffdInsights"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Direct oral anticoagulants (DOACs) have been increasingly prescribed instead of vitamin-K-antagonists (VKA) although VKAs cost considerably less than DOACs. In 2014, a new system for drug expenditures, the Wirkstoffvereinbarung (WSV, Active substance agreement), was implemented in Bavaria, Germany to control pharmaceutical expenditures transparently. Achieving the targets for the VKAs set by the WSV was difficult for general practitioners (GPs). We explored the determinants of prescribing VKAs (specifically phenprocoumon) versus DOACs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Qualitative interviews (n\u2009=\u200918) and two small group discussions (n\u2009=\u200910) were conducted with GPs. For the qualitative content analysis, we formed a system of categories based on the domains of the Theoretical Domains Framework (TDF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Participants actively weighed various factors when deciding between prescribing phenprocoumon or DOACs. Costs played a subordinate role although all participants were aware that DOACs come at a higher cost than phenprocoumon. Trend reports served as a tool for GPs to assess their prescribing practices, however did not lead to a change in prescribing behaviour. The interviewees had a very heterogeneous view of safety, effect, and evidence of phenprocoumon or DOACs. The cooperation of the patients is crucial. Time is a significant challenge for participants when initiating patients on or switching them to phenprocoumon, which is especially problematic as all of the patients discharged from the hospital are put on DOACs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>GPs are caught between economic requirements, patients\u2019 wishes, and good collegial cooperation when deciding for or against phenprocoumon. As oral anticoagulant therapy (OAC) is mostly initiated in the hospital, and as physicians almost exclusively prescribe DOACs there, participating GPs feel overchallenged in reaching the targets set by the WSV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number:<\/jats:title>\n                    <jats:p>Main ID: DRKS00019820 (German Register of Clinical Studies and World Health Organization).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11786329251341083","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T10:29:00Z","timestamp":1750501740000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prescribing Vitamin-K-Antagonists Versus Direct Oral Anticoagulants Among Bavarian General Practitioners: A Qualitative Study"],"prefix":"10.1177","volume":"18","author":[{"given":"Nikoletta","family":"Zeschick","sequence":"first","affiliation":[{"name":"Institute of General Practice, Friedrich-Alexander-University Erlangen-N\u00fcrnberg, University Hospital Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2804-5660","authenticated-orcid":false,"given":"Julia","family":"Gollnick","sequence":"additional","affiliation":[{"name":"Institute of General Practice\/Family Medicine, Philipps University of Marburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Muth","sequence":"additional","affiliation":[{"name":"Institute of General Practice\/Family Medicine, Philipps University of Marburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"H\u00f6rbrand","sequence":"additional","affiliation":[{"name":"Association of Statutory Health Insurance Physicians, Bavaria, M\u00fcnchen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Killian","sequence":"additional","affiliation":[{"name":"Association of Statutory Health Insurance Physicians, Bavaria, M\u00fcnchen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Donner-Banzhoff","sequence":"additional","affiliation":[{"name":"Institute of General Practice\/Family Medicine, Philipps University of Marburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"K\u00fchlein","sequence":"additional","affiliation":[{"name":"Institute of General Practice, Friedrich-Alexander-University Erlangen-N\u00fcrnberg, University Hospital Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0838-7989","authenticated-orcid":false,"given":"Maria","family":"Sebasti\u00e3o","sequence":"additional","affiliation":[{"name":"Institute of General Practice, Friedrich-Alexander-University Erlangen-N\u00fcrnberg, University Hospital Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.118.006273"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.22.8.983"},{"key":"e_1_3_3_4_2","author":"Arzneimittelkommission der deutschen \u00c4rzteschaft (Akd\u00c4)","year":"2019","unstructured":"Arzneimittelkommission der deutschen \u00c4rzteschaft (Akd\u00c4). Orale Antikoagulation bei nicht valvul\u00e4rem Vorhofflimmern Empfehlungen zum Einsatz der direkten oralen Antikoagulanzien Dabigatran, Apixaban, Edoxaban und Rivaroxaban. Akd\u00c4, 2019.","journal-title":"Orale Antikoagulation bei nicht valvul\u00e4rem Vorhofflimmern Empfehlungen zum Einsatz der direkten oralen Antikoagulanzien Dabigatran, Apixaban, Edoxaban und Rivaroxaban"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-015363"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-022-00389-9"},{"key":"e_1_3_3_7_2","first-page":"1","article-title":"Real-world effectiveness and safety of oral anticoagulation strategies in atrial fibrillation: a cohort study based on a German claims dataset","volume":"9","author":"Mueller S","year":"2018","unstructured":"Mueller S, Groth A, Spitzer SG, Schramm A, Pfaff A, Maywald U. Real-world effectiveness and safety of oral anticoagulation strategies in atrial fibrillation: a cohort study based on a German claims dataset. Pragmat Obs Res. 2018;9:1-10.","journal-title":"Pragmat Obs Res"},{"key":"e_1_3_3_8_2","first-page":"531","volume-title":"Arzneiverordnungs-Report 2019","author":"Hein L","unstructured":"Hein L, Wille H. Antithrombotika und Antih\u00e4morrhagika. In: Schwabe U, Paffrath D, Ludwig W-D, Klauber J, eds. Arzneiverordnungs-Report 2019. Springer; 2019:531-555."},{"key":"e_1_3_3_9_2","unstructured":"KVB FORUM. Steuern statt pr\u00fcfen \u2013 zwei Jahre Bayerische Wirkstoffvereinbarung [Control instead of audit \u2013 two years of Bavarian active substance agreement]. 2022. Updated 6 March 2020. Accessed 29 April 2022. https:\/\/www.kvb.de\/fileadmin\/kvb\/dokumente\/Presse\/Publikation\/KVB-FORUM\/Einzeldateien-FORUM\/2016\/KVB-FORUM-11-2016-Titelthema-Wirkstoffvereinbarung.pdf"},{"key":"e_1_3_3_10_2","unstructured":"Bundesministerium f\u00fcr Gesundheit. Richtgr\u00f6\u00dfen und Wirtschaftlichkeitspr\u00fcfung [Benchmarks and performance audit]. 2022. Updated 5 August 2016. Accessed 29 April 2022. https:\/\/www.bundesgesundheitsministerium.de\/service\/begriffe-von-a-z\/r\/richtgroessen-und-wirtschaftlichkeitspruefung.html"},{"key":"e_1_3_3_11_2","unstructured":"Kassen\u00e4rztliche Vereinigung Bayerns. Wirkstoffvereinbarung vom 01.10.2017 [Active substance agreement from 10\/01\/2017]. 2022. Updated 1 October 2017. Accessed 29 April 2022. https:\/\/www.kvb.de\/fileadmin\/kvb\/dokumente\/Praxis\/Rechtsquellen\/S-Z\/KVB-RQ-Wirkstoffvereinbarung-2017.pdf"},{"key":"e_1_3_3_12_2","unstructured":"Gemeinsamer Bundesausschuss (G-BA). WirtMed \u2013 Die Verordnung von Arzneimitteln: Pr\u00fcfung und Steuerung von Wirtschaftlichkeit und Qualit\u00e4t (WirtMed-Studie) [WirtMed \u2013 The prescription of drugs: examination and control of efficiency and quality (WirtMed Study)]. 2022. Accessed 29 April 2022. https:\/\/innovationsfonds.g-ba.de\/projekte\/versorgungsforschung\/wirtmed-die-verordnung-von-arzneimitteln-pruefung-und-steuerung-von-wirtschaftlichkeit-und-qualitaet-wirtmed-studie.133"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-022-03563-6"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-024-12189-0"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph21091174"},{"key":"e_1_3_3_16_2","unstructured":"Dresing T Pehl T. Praxisbuch interview transkription & analyse audiotranskription [Interview practice book transcription & analysis audio transcription]. 2022. Accessed 29 April 2022. https:\/\/www.audiotranskription.de\/wp-content\/uploads\/2020\/11\/Praxisbuch_08_01_web.pdf"},{"key":"e_1_3_3_17_2","first-page":"601","volume-title":"Handbuch Qualitative Forschung in Der Psychologie","author":"Mayring P","unstructured":"Mayring P. Qualitative inhaltsanalyse. In: Mey G, Mruck K, eds. Handbuch Qualitative Forschung in Der Psychologie. Springer; 2010:601-613."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-023-09844-3"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-7-37"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/qshc.2004.011155"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzm042"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1055\/a-1778-3831"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13299"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euu225"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/joa3.12588"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2012.05.011"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.3399\/BJGPO.2022.0179"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-016-1452-2"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2022.101861"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-021-01453-5"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.8254"},{"issue":"1","key":"e_1_3_3_32_2","first-page":"1416","article-title":"The role Of NOACs in atrial fibrillation management: a qualitative study","volume":"9","author":"Kirley K","year":"2016","unstructured":"Kirley K, GouthamRao Bauer V, Masi C. The role Of NOACs in atrial fibrillation management: a qualitative study. J Atr Fibrillation. 2016;9(1):1416.","journal-title":"J Atr Fibrillation"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036493"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.36469\/9774"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/hec.4650"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.464"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1547-5069.2003.tb00001.x"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.21.joc60162"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-66303-5"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2015.09.023"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2021.03.003"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12471-019-01331-x"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-10-0757"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001768"},{"key":"e_1_3_3_45_2","first-page":"279","volume-title":"Arzneimittel-Kompass 2022: Qualit\u00e4t der Arzneimittelversorgung","author":"Busse R","unstructured":"Busse R, Henschke C, Panteli D, Vogler S. Arzneimittelmarkt und -versorgung in Deutschland im europ\u00e4ischen Vergleich. In: Schr\u00f6der H, Th\u00fcrmann P, Telschow C, Schr\u00f6der M, Busse R eds. Arzneimittel-Kompass 2022: Qualit\u00e4t der Arzneimittelversorgung. Springer Berlin Heidelberg; 2022:279-303."},{"key":"e_1_3_3_46_2","unstructured":"Kassen\u00e4rztliche Vereinigung Bayerns. Wirkstoffvereinbarung \u2013 tempor\u00e4re Aussetzung der Antikoagulantien-Ziele 26.1 und 26.2 ab dem 01.04.2024 [WSV \u2013 Temporary suspension of anticoagulant targets 26.1 and 26.2 from 1 April 2024]. 2024. Accessed 1 April 2025. https:\/\/www.kvb.de\/fileadmin\/kvb\/Mitglieder\/Service\/Serviceschreiben\/2024-DS\/KVB-RS-240328-WIS-Aussetzten-Antikoagulantienziele-26-1-und-26-2.pdf"}],"container-title":["Health Services Insights"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11786329251341083","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11786329251341083","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11786329251341083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:09:18Z","timestamp":1777450158000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11786329251341083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":45,"alternative-id":["10.1177\/11786329251341083"],"URL":"https:\/\/doi.org\/10.1177\/11786329251341083","relation":{},"ISSN":["1178-6329","1178-6329"],"issn-type":[{"value":"1178-6329","type":"print"},{"value":"1178-6329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"article-number":"11786329251341083"}}